Quality Care
The program comes a week after the digital mental health company replaced its CEO.
The company develops a breakthrough device for detecting residual cancer tissues.
Also: Pear Therapeutics reported $2.7 million in revenue for its first quarter compared with $1.3 million in Q4 2021.
Cerebral is halting prescriptions such as Adderall and Xanax for current and new patients.
Authors of the study said the results raise concerns about worsening health disparities, especially when models can detect self-reported race information where human radiologists can't.
The company said the Series B brings its total raise to $45 million.
The startup also announced a new product called Clear Contracts that aims to improve the direct contracting process.
The clinical trial with Huntsville Heart Center is expected to be completed by October.
The suspension comes as the digital mental health company faces increasing pressure over its prescription practices, particularly for ADHD medications.
The AI tech can spot signs of pancreatic cancer from non-contrast CT images.